Zhiming Shao

50PUBLICATIONS

116CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsTumour immunology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (50)

Sort by Publication Date:

|Jun 18, 2026

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.

|Apr 13, 2026

Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.

Yaxin Zhao, Han Wang, Ying Wang

|Mar 11, 2026

Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.

Xiao-Hong Ding, Fenfang Chen, Fan Yang

|Mar 06, 2026

Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors.

Di Shao, Tianjian Yu, Yi Xiao

|Feb 15, 2026

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2- Breast Cancer.

Yi-Yu Chen, Yi-Fan Zhou, Xuan Qi

|Jan 28, 2026

TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.

Wen-Ya Wu, Yun-Song Yang, Lisa Andriani

Pageof 9

Frequent Collaborators

16 joint publications

Yi-Zhou Jiang

Ding Ma

Yi Xiao

Xi Jin

Wen-Tao Yang

Cai-Jin Lin

Tong Fu

Jiong Wu

Lei-Jie Dai

Gen-Hong Di

Frequent Collaborators

16 joint publications

Yi-Zhou Jiang

9 joint publications

Ding Ma

7 joint publications

Yi Xiao

5 joint publications

Xi Jin